Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 May;36(5):281-92.
doi: 10.1016/j.pediatrneurol.2007.02.008.

The neuropharmacology of the ketogenic diet

Affiliations
Review

The neuropharmacology of the ketogenic diet

Adam L Hartman et al. Pediatr Neurol. 2007 May.

Abstract

The ketogenic diet is a valuable therapeutic approach for epilepsy, one in which most clinical experience has been with children. Although the mechanism by which the diet protects against seizures is unknown, there is evidence that it causes effects on intermediary metabolism that influence the dynamics of the major inhibitory and excitatory neurotransmitter systems in brain. The pattern of protection of the ketogenic diet in animal models of seizures is distinct from that of other anticonvulsants, suggesting that it has a unique mechanism of action. During consumption of the ketogenic diet, marked alterations in brain energy metabolism occur, with ketone bodies partly replacing glucose as fuel. Whether these metabolic changes contribute to acute seizure protection is unclear; however, the ketone body acetone has anticonvulsant activity and could play a role in the seizure protection afforded by the diet. In addition to acute seizure protection, the ketogenic diet provides protection against the development of spontaneous recurrent seizures in models of chronic epilepsy, and it has neuroprotective properties in diverse models of neurodegenerative disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Alterations in intermediary metabolism during the high-fat, low-carbohydrate ketogenic diet that lead to the formation of ketone bodies. The ketogenic diet provides high levels of long chain fatty acids and is deficient in carbohydrates so that glucose availability is severely limited. The demand to maintain serum glucose causes oxaloacetate to be shunted from the Krebs cycle to the pathway for gluconeogenesis, a multistep process that is the reverse of glycolysis. As a result of diminished oxaloacetate, the Krebs cycle has reduced capacity to handle the high levels of acetyl-CoA generated from fat. Instead, acetyl-CoA is converted to the ketone body acetoacetate which spontaneously degrades to acetone. Acetoacetate also is converted enzymatically to β-hydroxybutyrate in a reversible reaction catalyzed by the NADH-dependent mitochondrial enzyme β-hydroxybutyrate dehydrogenase. Ketone bodies represent alternative energy substrates for the brain. Not all Krebs cycle intermediates are shown in the schematic. Abbreviations: CAT, carnitine-acylcarnitine translocase; LCFA, long chain fatty acids; MCT, monocarboxylic acid transporter.
Figure 2
Figure 2
Alterations in the metabolism of excitatory amino acids and γ-aminobutyric acid (GABA) during the high-fat, low-carbohydrate ketogenic diet. Metabolism of acetyl-CoA generated from fats leads to high consumption of oxaloacetate (see Fig. 1). L-Aspartate, a nonessential amino acid, is formed by the transamination of oxaloacetate with an amino group from glutamate. Reduced availability of oxaloacetate along with robust availability of α-ketoglutarate from high activity of the first part of the Krebs cycle leads to low aspartate levels. It has been hypothesized that more glutamate is thus accessible to glutamic acid decarboxylase for production of GABA [33]. Not all Krebs cycle intermediates are shown in the schematic.

References

    1. Freeman J, Veggiotti P, Lanzi G, Tagliabue A, Perucca E. The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res. 2006;68:145–80. - PubMed
    1. Bailey EE, Pfeifer HH, Thiele EA. The use of diet in the treatment of epilepsy. Epilepsy Behav. 2005;6:4–8. - PubMed
    1. Rogawski MA. Principles of antiepileptic drug action. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic drugs. 5. Philadelphia: Lippincott Williams & Wilkins; 2002. pp. 3–22.
    1. Macdonald RL, Rogawski MA. Cellular effects of antiepileptic drugs. In: Engel J Jr, Pedley TA, Aicardi J, Dichter MA, Moshé S, Perucca E, et al., editors. Epilepsy: a comprehensive textbook. 2. Philadelphia: Lippincott Williams & Wilkins; 2007. in press.
    1. Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol. 2006;17:431–9. - PMC - PubMed

Publication types